How to buy Ligand Pharmaceuticals Incorporated stock (LGND)

Ligand Pharmaceuticals Incorporated is a biotechnology business based in the US. Ligand Pharmaceuticals Incorporated shares (LGND) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $114.64 – a decrease of 1.94% over the previous week. Ligand Pharmaceuticals Incorporated employs 58 staff and has a trailing 12-month revenue of around $152.4 million.

Our top picks for where to buy Ligand Pharmaceuticals Incorporated stock

Buy Ligand Pharmaceuticals Incorporated stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ligand Pharmaceuticals Incorporated stock price (NASDAQ: LGND)

Use our graph to track the performance of LGND stocks over time.

Ligand Pharmaceuticals Incorporated shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$114.64
52-week range	$67.53 - $129.90
50-day moving average more info button	$114.34
200-day moving average more info button	$94.91
Wall St. target price	$144.00
PE ratio more info button	45.9478
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$2.49

Is it a good time to buy Ligand Pharmaceuticals Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ligand Pharmaceuticals Incorporated price performance over time

Historical closes compared with the close of $113.95 from 2024-12-19

1 week (2024-12-13)	-2.53%
1 month (2024-11-21)	-2.23%
3 months (2024-09-20)	10.85%
6 months (2024-06-21)	43.53%

1 year (2023-12-21)	60.88%
2 years (2022-12-21)	74.58%
3 years (2021-12-21)	20.95%
5 years (2019-12-20)	72.53%

Is Ligand Pharmaceuticals Incorporated stock undervalued or overvalued?

Valuing Ligand Pharmaceuticals Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ligand Pharmaceuticals Incorporated's P/E ratio

Ligand Pharmaceuticals Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, Ligand Pharmaceuticals Incorporated shares trade at around 46x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Ligand Pharmaceuticals Incorporated's PEG ratio

Ligand Pharmaceuticals Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5271. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Ligand Pharmaceuticals Incorporated's EBITDA

Ligand Pharmaceuticals Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $52.6 million.

The EBITDA is a measure of a Ligand Pharmaceuticals Incorporated's overall financial performance and is widely used to measure a its profitability.

Ligand Pharmaceuticals Incorporated financials

Revenue TTM	$152.4 million
Operating margin TTM	21.14%
Gross profit TTM	$107.3 million
Return on assets TTM	1.3%
Return on equity TTM	6%
Profit margin	29.68%
Book value	$44.84
Market Capitalization more info button	$2.2 billion

TTM: trailing 12 months

Ligand Pharmaceuticals Incorporated share dividends

We're not expecting Ligand Pharmaceuticals Incorporated to pay a dividend over the next 12 months.

Have Ligand Pharmaceuticals Incorporated's shares ever split?

Ligand Pharmaceuticals Incorporated's shares were split on a 1603:1000 basis on 1 November 2022 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1603 shares. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals Incorporated shares – just the quantity. However, indirectly, the new 37.6% lower share price could have impacted the market appetite for Ligand Pharmaceuticals Incorporated shares which in turn could have impacted Ligand Pharmaceuticals Incorporated's share price.

Ligand Pharmaceuticals Incorporated share price volatility

Over the last 12 months, Ligand Pharmaceuticals Incorporated's shares have ranged in value from as little as $67.53 up to $129.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals Incorporated's is 0.896. This would suggest that Ligand Pharmaceuticals Incorporated's shares are less volatile than average (for this exchange).

Ligand Pharmaceuticals Incorporated overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Frequently asked questions

What percentage of Ligand Pharmaceuticals Incorporated is owned by insiders or institutions?
Currently 1.878% of Ligand Pharmaceuticals Incorporated shares are held by insiders and 100.261% by institutions. How many people work for Ligand Pharmaceuticals Incorporated?
Latest data suggests 58 work at Ligand Pharmaceuticals Incorporated. When does the fiscal year end for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated's fiscal year ends in December. Where is Ligand Pharmaceuticals Incorporated based?
Ligand Pharmaceuticals Incorporated's address is: 555 Heritage Drive, Jupiter, FL, United States, 33458 What is Ligand Pharmaceuticals Incorporated's ISIN number?
Ligand Pharmaceuticals Incorporated's international securities identification number is: US53220K5048 What is Ligand Pharmaceuticals Incorporated's CUSIP number?
Ligand Pharmaceuticals Incorporated's Committee on Uniform Securities Identification Procedures number is: 53220K199